Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2020-12-02 | Krisztina Zsebo, Ph.D. was nominated to our board of directors in November 2020 and is a biopharmaceutical veteran with 36 years of experience in the biotechnology industry. She has served as the CEO and co-founder of VasoRx since April 2018. Since August 2015, she has been a consultant in the biotechnology industry as President of Biovest Consulting, LLC and since June 2020, she has served as the CEO of VST-Bio Corporation, an early stage biotechnology company. |
| 2021-04-30 | Krisztina Zsebo, Ph.D. was appointed to our board of directors in December 2020 ... (3)(4) Member of the audit committee and science and technology committee ... The following table sets forth summary information concerning the compensation awarded to, paid to, or earned by the non-employee members of our board of directors for the fiscal year ended December 31, 2020: ... Krisztina Zsebo, Ph.D. $ 844 ... |
| 2022-04-27 | Krisztina Zsebo, Ph.D.(3)(4) 66 Director 2020 2023; Member of the audit committee; Member of the science and technology committee; The following table sets forth summary information concerning the compensation awarded to, paid to, or earned by the non-employee members of our board of directors for the fiscal year ended December 31, 2021: Krisztina Zsebo, Ph.D. $42,375 Fees Earned or Paid in Cash, $11,874 Stock Awards, $47,559 Option Awards, Total $101,808. |
| 2023-09-01 | Krisztina Zsebo, Ph.D. was appointed to our board of directors in December 2020 and is a biopharmaceutical veteran with more than 35 years of experience in the biotechnology industry. Since August 2015, she has been a consultant in the biotechnology industry as President of Biovest Consulting, LLC. She has recently resumed her roles as the CEO of VasoRx, Inc., where she served from 2018 to 2022, and as the CEO of VST-BIO Corp., an early-stage biotechnology company, where she served from 2020 to 2022. From 2004 through 2015, she was CEO & President and a director of Celladon Corporation (now Eiger BioPharmaceuticals, Inc.) and took the company public. From 2004 to 2007, Dr. Zsebo was a venture partner at Enterprise Partners Venture Capital, a venture capital firm. Prior to joining Enterprise Partners, Dr. Zsebo held executive positions at Remedyne Corporation, a biotechnology company, Connetics Corporation, a specialty pharmaceutical company, ALZA Corporation, a pharmaceutical and medical systems company, Cell Genesys, Inc., a biotechnology company, and Amgen Inc., a biotechnology company. Dr. Zsebo received a B.S. in Biochemistry from the University of Maryland, an M.S. in Biochemistry and Biophysics from Oregon State University and a Ph.D. in Comparative Biochemistry from the University of California, Berkeley. |
Data sourced from SEC filings. Last updated: 2026-02-03